GHRP-6 vs GHRP-2 vs Hexarelin: Growth Hormone Releasing Peptide Comparison

Three Hexapeptide GHRPs in Research

The GHRP (Growth Hormone Releasing Peptide) compound class includes three foundational hexapeptide research compounds: GHRP-6, GHRP-2 (Pralmorelin), and Hexarelin (Examorelin). All three are synthetic hexapeptide GHS-R1a agonists driving GH pulse amplification at the pituitary somatotroph, but the receptor binding profiles and downstream pharmacology differ — making the trio a comparative pharmacology research tool framework. All three are available at Advanced Peptide Science within the Growth Hormone & Performance category.

Research Background

The GHRP class emerged from medicinal-chemistry programmes designing synthetic ghrelin-receptor agonists. GHRP-6 was the first compound, followed by GHRP-2 (with reduced side-effect profile) and Hexarelin (with high potency and CD36 receptor cross-reactivity). The selective pentapeptide Ipamorelin (within the CJC-1295 + Ipamorelin Blend) represents a later generation with further-refined receptor selectivity.

Mechanism Comparison

All three compounds act primarily through GHS-R1a (ghrelin receptor), a Gq-coupled class A GPCR coupled to PLC/IP3 signalling driving GH pulse amplification at pituitary somatotrophs. The downstream GH-axis effects are mechanistically similar across the three compounds. The research-relevant differences lie in (1) receptor binding affinity, (2) downstream pathway selectivity within GHS-R1a signalling, and (3) cross-reactivity with other receptor systems — most notably Hexarelin’s additional binding at CD36 in cardiac tissue.

Key Research Findings

Appetite-Pathway Engagement (GHRP-6)

GHRP-6 has the broadest ghrelin-pathway engagement of the three compounds, including substantial activation of arcuate-nucleus appetite-regulation circuitry. This makes GHRP-6 a research tool for combined GH-axis + appetite-pathway studies, where both effects are intended endpoints. The appetite component is reduced in GHRP-2 and Hexarelin.

Reduced Side-Effects (GHRP-2)

GHRP-2 (Pralmorelin, H-D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2) was developed as a refinement of GHRP-6 with reduced appetite-stimulation in preclinical models. The structural changes (notably the D-2-Nal substitution at position 2) shift the receptor binding profile to reduce ghrelin-pathway side-effects while retaining GH-secretagogue activity.

Cardiac CD36 Binding (Hexarelin)

Hexarelin (Examorelin, His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) is the most potent GH-releasing GHRP and uniquely binds the scavenger receptor CD36 in cardiac tissue — opening a research line investigating direct cardioprotective signalling independent of GH-pathway effects. This cardiac binding distinguishes Hexarelin within the GHRP class.

Research Applications and Comparison

The three compounds enable parallel research investigating receptor-binding-profile effects within the GHRP class. Researchers can compare appetite-pathway engagement (GHRP-6 > GHRP-2 > Hexarelin), GH-secretagogue potency (Hexarelin > GHRP-2 ≈ GHRP-6), and cardiac CD36 binding (Hexarelin only). Extended comparative research is supported by including the selective pentapeptide Ipamorelin (within the CJC-1295 + Ipamorelin Blend) and combined GHRH + GHRP research via the GH Blend.

Side-by-Side Research Specifications

Parameter	GHRP-6	GHRP-2	Hexarelin
Molecular Weight	873.0 Da	817.9 Da	887.1 Da
Sequence (position 2)	D-Trp	D-2-Nal	D-2-MeTrp
Primary Receptor	GHS-R1a	GHS-R1a	GHS-R1a + CD36
Appetite Engagement	High	Reduced	Reduced
GH Potency	Standard	Standard	High
Distinctive Feature	Foundational GHRP	Reduced side-effects	Cardiac CD36 binding

Frequently Asked Questions

Which GHRP is best for research?

The most appropriate GHRP depends on the research question. GHRP-6 for studies engaging the ghrelin appetite pathway; GHRP-2 for GH-axis research with reduced appetite confounders; Hexarelin for high-potency GH research or cardiac CD36-pathway research. All three are available at Advanced Peptide Science.

How does Hexarelin’s CD36 binding matter?

CD36 is a scavenger receptor expressed in cardiac tissue. Hexarelin’s additional CD36 binding (alongside GHS-R1a) creates a research-tool framework for investigating direct cardioprotective signalling independent of GH-axis effects.

What does Pralmorelin refer to?

Pralmorelin is the chemical-research name for GHRP-2. The two terms refer to the same compound.

Are these compounds approved for human use?

Advanced Peptide Science supplies all three GHRPs exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.

---

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.